Mississippi defends managed care contracts against criticism from losing bidders

Two companies who weren’t chosen in bids for $2 billion in Medicaid managed care business in Mississippi have protested the decision, claiming the state scored them unfairly and chose a bidder with a connection with to the state Medicaid director.

The Mississippi Division of Medicaid said those criticisms were unfounded, according to the Jackson Clarion-Ledger. It defended the decision to choose UnitedHealthcare, Magnolia Health and Molina Healthcare of Mississippi over the two who have protested and sued the agency over the decision, Mississippi True and Amerigroup.

"The agency affirms its initial MississippiCAN contract award decisions," said David Dzielak, Mississippi's Medicaid Director. "The protests were without merit, and the allegations against me and the agency were disingenuous. The MississippiCAN procurement process was conducted with the highest professional standards, and we look forward to working with Magnolia, Molina, and United to provide our members with access to quality healthcare."

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.